Stay updated with breaking news from Vaccine Development Program In Collaboration. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Issuer: CureVac / Key word(s): Study results05.01.2024 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platf...
Issuer: CureVac / Key word: Study results CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong...
Issuer: CureVac / Key word(s): Study results 05.01.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform Head-to-head comparison with licensed bivalent mRNA-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profile Monovalent